Grand Pharmaceutical Group Ltd
HKEX:512
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Grand Pharmaceutical Group Ltd
Tax Provision
Grand Pharmaceutical Group Ltd
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Tax Provision
-HK$249.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-20%
|
|
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
Tax Provision
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Tax Provision
-¥446.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-15%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Tax Provision
-¥1.6B
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Tax Provision
-HK$2.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Tax Provision
-$63.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-67%
|
CAGR 10-Years
-44%
|
|
Grand Pharmaceutical Group Ltd
Glance View
Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.
See Also
What is Grand Pharmaceutical Group Ltd's Tax Provision?
Tax Provision
-249.8m
HKD
Based on the financial report for Dec 31, 2025, Grand Pharmaceutical Group Ltd's Tax Provision amounts to -249.8m HKD.
What is Grand Pharmaceutical Group Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
-20%
Over the last year, the Tax Provision growth was 35%. The average annual Tax Provision growth rates for Grand Pharmaceutical Group Ltd have been 16% over the past three years , 3% over the past five years , and -20% over the past ten years .